Le prix convenu sur cette offre est de 5 dollars et 20 cents
J'ai vu l'accord de Nestlé S.A.
J'ai raison. J'ai dit du 5 au 9 juin pour un accord.
119000000 À 5.20
Recent MCRB News
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/07/2024 08:00:00 PM
- Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science • GlobeNewswire Inc. • 06/06/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:23:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:18:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:18:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:17:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:16:18 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 02:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:05:54 AM
- Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates • Business Wire • 05/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:18:07 PM
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/06/2024 08:01:00 PM
- Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 • Business Wire • 05/06/2024 01:30:00 PM
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT • Business Wire • 04/09/2024 11:00:00 AM
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/28/2024 11:00:00 AM
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/19/2024 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/05/2024 03:18:19 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2024 03:13:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:05:53 PM
- Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • Business Wire • 03/05/2024 12:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 • Business Wire • 02/28/2024 12:00:00 PM
- Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference • Business Wire • 02/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:06:02 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM